Market closedNon-fractional
Xilio Therapeutics/XLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Ticker
XLO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
56
Website
xiliotx.com
XLO Metrics
BasicAdvanced
$35M
Market cap
-
P/E ratio
-$2.57
EPS
-0.04
Beta
-
Dividend rate
Price and volume
Market cap
$35M
Beta
-0.04
Financial strength
Current ratio
2.191
Quick ratio
2.026
Long term debt to equity
30.518
Total debt to equity
34.822
Interest coverage (TTM)
-120.24%
Management effectiveness
Return on assets (TTM)
-46.46%
Return on equity (TTM)
-128.37%
Valuation
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-0.489
Growth
Earnings per share change (TTM)
-21.43%
3-year earnings per share growth (CAGR)
-71.11%
What the Analysts think about XLO
Analyst Ratings
Majority rating from 3 analysts.
XLO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
-2.27%
Profit margin
0.00%
NaN%
XLO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.61
-$0.64
-$0.62
-
Expected
-$0.87
-$0.81
-$0.64
-$0.11
-$0.23
Surprise
-19.31%
-24.46%
0.00%
463.64%
-
XLO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xilio Therapeutics stock?
Xilio Therapeutics (XLO) has a market cap of $35M as of July 27, 2024.
What is the P/E ratio for Xilio Therapeutics stock?
The price to earnings (P/E) ratio for Xilio Therapeutics (XLO) stock is 0 as of July 27, 2024.
Does Xilio Therapeutics stock pay dividends?
No, Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Xilio Therapeutics dividend payment date?
Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xilio Therapeutics?
Xilio Therapeutics (XLO) has a beta rating of -0.04. This means that it has an inverse relation to market volatility.
Buy or sell Xilio Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.